Literature DB >> 34271216

Defining a Severe Asthma Super-Responder: Findings from a Delphi Process.

John W Upham1, Chantal Le Lievre2, David J Jackson3, Matthew Masoli4, Michael E Wechsler5, David B Price6.   

Abstract

BACKGROUND: Clinicians are increasingly recognizing severe asthma patients in whom biologics and other add-on therapies lead to dramatic improvement. Currently, there is no agreed-upon super-responder (SR) definition.
OBJECTIVE: To survey severe asthma experts using a modified Delphi process, to develop an international consensus-based definition of a severe asthma SR.
METHODS: The Delphi panel was composed of 81 participants (94% specialist pulmonologists or allergists) from 24 countries and consisted of three iterative online voting rounds. Consensus on individual items, whether acceptance or rejection, required at least 70% agreement by panel members.
RESULTS: Consensus was achieved that the SR definition should be based on improvement across three or more domains assessed over 12 months. Major SR criteria included exacerbation elimination, a large improvement in asthma control (two or more times the minimal clinically important difference), and cessation of maintenance of oral steroids (or weaning to adrenal insufficiency). Minor SR criteria were composed of a 75% exacerbation reduction, having well-controlled asthma, and 500 mL or greater improvement in FEV1. The SR definition requires improvement in at least two major criteria. In the future, the SR definition should be expanded to incorporate quality of life measures, although current tools can be difficult to implement in a clinical setting and further research is needed.
CONCLUSIONS: This international consensus-based definition of severe asthma SRs is an important prerequisite for better understanding SR prevalence, predictive factors, and the mechanisms involved. Further research is needed to understand the patient's perspective and to measure quality of life more precisely in SRs.
Copyright © 2021 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  Asthma; Asthma treatment; Biologics

Mesh:

Year:  2021        PMID: 34271216     DOI: 10.1016/j.jaip.2021.06.041

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  10 in total

Review 1.  Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.

Authors:  Kazuki Hamada; Keiji Oishi; Yoriyuki Murata; Tsunahiko Hirano; Kazuto Matsunaga
Journal:  J Asthma Allergy       Date:  2021-12-07

2.  Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study.

Authors:  Takanori Numata; Jun Araya; Hanae Miyagawa; Keitaro Okuda; Daisuke Takekoshi; Mitsuo Hashimoto; Shunsuke Minagawa; Takeo Ishikawa; Hiromichi Hara; Kazuyoshi Kuwano
Journal:  J Asthma Allergy       Date:  2022-04-01

Review 3.  Biologics in Asthma: A Molecular Perspective to Precision Medicine.

Authors:  Brittany Salter; Paige Lacy; Manali Mukherjee
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

4.  Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.

Authors:  Andrew Menzies-Gow; Flavia L Hoyte; David B Price; David Cohen; Peter Barker; James Kreindler; Maria Jison; Christopher L Brooks; Peggy Papeleu; Rohit Katial
Journal:  Adv Ther       Date:  2022-03-14       Impact factor: 4.070

5.  Improving Care in Eosinophil-Associated Diseases: A Charter.

Authors:  David J Jackson; Praveen Akuthota; Rebeca Andradas; Albert J Bredenoord; Amanda Cordell; Sarah Gray; Joyce Kullman; Sameer K Mathur; Ian Pavord; Florence Roufosse; Christian Rubio; Irena Clisson Rusek; Dagmar Simon; Mary Jo Strobel; Tonya Winders
Journal:  Adv Ther       Date:  2022-04-30       Impact factor: 4.070

6.  Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab".

Authors:  Luigino Calzetta; Paola Rogliani
Journal:  Adv Ther       Date:  2022-06-22       Impact factor: 4.070

7.  Towards precision drug therapy in asthma.

Authors:  Job F M van Boven
Journal:  Ann Transl Med       Date:  2022-09

8.  A Single Center Experience of Super-Responders Among Severe Asthma Patients Receiving Treatment with Mepolizumab.

Authors:  Emel Atayık; Gökhan Aytekin
Journal:  Turk Thorac J       Date:  2022-09

Review 9.  Evolving Concept of Severe Asthma: Transition From Diagnosis to Treatable Traits.

Authors:  So-Young Park; Sung-Yoon Kang; Woo-Jung Song; Joo-Hee Kim
Journal:  Allergy Asthma Immunol Res       Date:  2022-09       Impact factor: 5.096

10.  Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register.

Authors:  Marianne Baastrup Soendergaard; Susanne Hansen; Anne-Sofie Bjerrum; Ole Hilberg; Sofie Lock-Johansson; Kjell Erik Julius Håkansson; Truls Sylvan Ingebrigtsen; Claus Rikard Johnsen; Linda Makowska Rasmussen; Anna von Bülow; Karin Dahl Assing; Johannes Martin Schmid; Charlotte Suppli Ulrik; Celeste Porsbjerg
Journal:  ERJ Open Res       Date:  2022-10-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.